Patents by Inventor Gaetano Brambilla
Gaetano Brambilla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11213485Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.Type: GrantFiled: November 20, 2019Date of Patent: January 4, 2022Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
-
Patent number: 10993916Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.Type: GrantFiled: May 12, 2016Date of Patent: May 4, 2021Assignee: Chiesi Farmaceutici S.p.A.Inventors: Gaetano Brambilla, Paolo Colombo, Francesca Buttini, Michele Miozzi
-
Patent number: 10737044Abstract: Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 ?m.Type: GrantFiled: September 26, 2016Date of Patent: August 11, 2020Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Gaetano Brambilla, Robert Johnson, David Andrew Lewis
-
Publication number: 20200138724Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.Type: ApplicationFiled: January 9, 2020Publication date: May 7, 2020Applicant: Chiesi Farmaceutici S.p.A.Inventors: Gaetano BRAMBILLA, Paolo Colombo, Francesca Buttini, Michele Miozzi
-
Publication number: 20200085729Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.Type: ApplicationFiled: November 20, 2019Publication date: March 19, 2020Applicant: Chiesi Farmaceutici S.P.A.Inventors: David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
-
Patent number: 10525006Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.Type: GrantFiled: November 17, 2016Date of Patent: January 7, 2020Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: David Andrew Lewis, Brian John Meakin, Gaetano Brambilla
-
Publication number: 20170080168Abstract: Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 ?m.Type: ApplicationFiled: September 26, 2016Publication date: March 23, 2017Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Gaetano BRAMBILLA, Robert JOHNSON, David Andrew LEWIS
-
Publication number: 20170065518Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: DAVID ANDREW LEWIS, BRIAN JOHN MEAKIN, GAETANO BRAMBILLA
-
Patent number: 9566239Abstract: A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.Type: GrantFiled: September 22, 2014Date of Patent: February 14, 2017Assignee: VECTURA LIMITEDInventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini
-
Patent number: 9554992Abstract: Microparticles comprising a combination of an anticholinergic, a beta2-adrenoceptor agonist, and an inhaled corticosteroid are useful for the prevention and/or treatment of respiratory diseases.Type: GrantFiled: May 28, 2015Date of Patent: January 31, 2017Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Gaetano Brambilla, Michele Miozzi, Timothy J Rouse
-
Publication number: 20160324792Abstract: Crystalline microparticles consisting of a phenylalkylamino beta2-adrenergic agonist coated with a C12-C20 fatty acid are useful for the preparation of pharmaceutical aerosol formulations in form of suspension in a liquefied propellant gas or powder formulations.Type: ApplicationFiled: May 12, 2016Publication date: November 10, 2016Applicant: Chiesi Farmaceutici S.p.A.Inventors: Gaetano Brambilla, Paolo Colombo, Francesca Buttini, Michele Miozzi
-
Publication number: 20150352127Abstract: Microparticles comprising a combination of an anticholinergic, a beta2-adrenoceptor agonist, and an inhaled corticosteroid are useful for the prevention and/or treatment of respiratory diseases.Type: ApplicationFiled: May 28, 2015Publication date: December 10, 2015Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Gaetano BRAMBILLA, Michele MIOZZI, Timothy J. ROUSE
-
Publication number: 20150050350Abstract: A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.Type: ApplicationFiled: September 22, 2014Publication date: February 19, 2015Inventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini
-
Patent number: 8871274Abstract: A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.Type: GrantFiled: April 21, 2009Date of Patent: October 28, 2014Assignee: Vectura LimitedInventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini
-
Publication number: 20140060531Abstract: Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 ?m.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: Gaetano BRAMBILLA, Robert Johnson, Daivd Andrew Lewis
-
Patent number: 8420060Abstract: Pharmaceutical formulations comprising beclometasone dipropionate and a salt of formoterol exhibit improved stability and are useful in pressurized metered dose inhalers (pMDIs).Type: GrantFiled: October 4, 2010Date of Patent: April 16, 2013Assignee: Chiesi Farmaceutici S.p.A.Inventor: Gaetano Brambilla
-
Patent number: 8420058Abstract: Compositions which contain an active ingredient, a propellant containing a hydrofluoroalkane (HFA), a co-solvent, and a low-volatility component are useful for administering the active ingredient via an aerosol.Type: GrantFiled: August 26, 2009Date of Patent: April 16, 2013Assignee: Chiesi Farmaceutici S.p.A.Inventors: David Lewis, Davis Ganderton, Brian Meakin, Paolo Ventura, Gaetano Brambilla, Raffaella Garzia
-
Publication number: 20120308613Abstract: A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 ?m and a mass median diameter of at least 175 ?m; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.Type: ApplicationFiled: April 25, 2012Publication date: December 6, 2012Applicant: VECTURA LIMITEDInventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzno Ferrarini
-
Patent number: 8313732Abstract: A metal container and a method of preparing a metal container for a pharmaceutical formulation where the active ingredient is formoterol, a stereoisomer of formoterol, and a physiologically acceptable salt of formoterol, in a solution of a liquefied HFA propellant.Type: GrantFiled: September 1, 2010Date of Patent: November 20, 2012Assignee: Chiesi Farmaceutici S.p.A.Inventors: Rebecca Jaine Davies, David Ganderton, David Andrew Lewis, Brian John Meakin, Tanya Kathleen Church, Gaetano Brambilla, Alessandra Ferraris
-
Patent number: 8182791Abstract: A formulation for an inhaler device comprises carrier particles having a diameter of at least 50 ?m and a mass median diameter of at least 175 ?m; active particles; and additive material to which is able to promote release of the active particles from the carrier particles on actuation of the inhaler device. The formulation has excellent flowability even at relatively high fine particle contents.Type: GrantFiled: April 17, 2001Date of Patent: May 22, 2012Assignee: Vectura LimitedInventors: John Nicholas Staniforth, David Alexander Vodden Morton, Rajbir Gill, Gaetano Brambilla, Rossella Musa, Lorenzo Ferrarini